Home › Funds › ARMISTICE CAPITAL, LLC › DYN
ARMISTICE CAPITAL, LLC position in DYN
DYNE THERAPEUTICS INC · Health Care
ARMISTICE CAPITAL, LLC reported holding 2,678,060 shares of DYN (DYNE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$43.1M, representing 0.59% of its reported portfolio and ranking #17 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed DYN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How ARMISTICE CAPITAL, LLC's DYN position evolved
ARMISTICE CAPITAL, LLC first disclosed a stake in DYN in Q3 2023 at 1,200,000 shares (US$10.8M). The position peaked in Q2 2026 at 3,087,226 shares, worth US$68.6M. Across 13 filings, ARMISTICE CAPITAL, LLC increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,678,060 shares valued at US$43.1M — a reduction of -409,166 shares quarter over quarter.. Notable position changes include a 31% trim in Q4 2023 (shares rose 113% over the following quarter), a 187% increase in Q1 2025 (shares fell 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.20M | $10.75M | New |
| Q4 2023 | 824.00K | $10.96M | Reduce |
| Q1 2024 | 1.00M | $28.39M | Add |
| Q2 2024 | 970.89K | $34.26M | Reduce |
| Q3 2024 | 1.16M | $41.49M | Add |
| Q4 2024 | 964.52K | $22.72M | Reduce |
| Q1 2025 | 2.77M | $28.95M | Add |
| Q2 2025 | 2.56M | $24.37M | Reduce |
| Q3 2025 | 3.06M | $38.76M | Add |
| Q4 2025 | 3.25M | $63.56M | Add |
| Q1 2026 | 3.18M | $57.56M | Reduce |
| Q2 2026 | 3.09M | $68.57M | Reduce |
| Q3 2026 | 2.68M | $43.14M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DYN and 13F data
DYN (DYNE THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in DYN — the largest reported positions include Vestal Point Capital, LP (US$75.0M), TCG Crossover Management, LLC (US$74.3M), ORBIMED ADVISORS LLC (US$71.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DYN
- Vestal Point Capital, LP 3.38M sh · $74.96M · Q2 2026
- TCG Crossover Management, LLC 4.62M sh · $74.35M · Q3 2026
- ORBIMED ADVISORS LLC 3.24M sh · $71.86M · Q2 2026
- Frazier Life Sciences Management, L.P. 3.15M sh · $70.03M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.69M sh · $59.73M · Q2 2026
- FCPM III SERVICES B.V. 3.59M sh · $57.78M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 3.44M sh · $55.43M · Q3 2026
- Logos Global Management LP 3.00M sh · $48.33M · Q3 2026
- Venrock Adviser, LLC 2.17M sh · $48.28M · Q2 2026
- MPM BioImpact LLC 1.92M sh · $42.69M · Q2 2026
- Sofinnova Investments, Inc. 2.51M sh · $40.45M · Q3 2026
- Siren, L.L.C. 2.43M sh · $39.13M · Q3 2026
More on ARMISTICE CAPITAL, LLC
FAQ
How long has ARMISTICE CAPITAL, LLC held DYN?
ARMISTICE CAPITAL, LLC has disclosed DYN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is ARMISTICE CAPITAL, LLC's current position in DYN?
As of Q3 2026, ARMISTICE CAPITAL, LLC holds 2.68M shares of DYN (DYNE THERAPEUTICS INC), valued at $43.14M, representing 0.59% of its reported portfolio and ranking #17.
Has ARMISTICE CAPITAL, LLC been buying or selling DYN?
In the latest 13F filing (Q3 2026), ARMISTICE CAPITAL, LLC reduced its position in DYN. The position peaked in Q2 2026 at 3.09M shares.
Which other funds hold DYN?
Other major institutional holders of DYN include Vestal Point Capital, LP, TCG Crossover Management, LLC, ORBIMED ADVISORS LLC, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.